Meridian Wealth Management LLC trimmed its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 6.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,372 shares of the biopharmaceutical company’s stock after selling 164 shares during the period. Meridian Wealth Management LLC’s holdings in Alexion Pharmaceuticals were worth $311,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Investors Research Corp acquired a new position in shares of Alexion Pharmaceuticals during the 1st quarter worth approximately $27,000. Thor Advisors LLC acquired a new position in shares of Alexion Pharmaceuticals during the 1st quarter worth approximately $34,000. NEXT Financial Group Inc acquired a new position in shares of Alexion Pharmaceuticals during the 2nd quarter worth approximately $36,000. Berman Capital Advisors LLC raised its position in shares of Alexion Pharmaceuticals by 68.6% during the 1st quarter. Berman Capital Advisors LLC now owns 322 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 131 shares during the last quarter. Finally, Institutional & Family Asset Management LLC raised its position in shares of Alexion Pharmaceuticals by 39.5% during the 1st quarter. Institutional & Family Asset Management LLC now owns 307 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 87 shares during the last quarter. Institutional investors own 94.74% of the company’s stock.
In other news, Director Bros. Advisors Lp Baker sold 123,489 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $126.53, for a total transaction of $15,625,063.17. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Aradhana Sarin sold 578 shares of the business’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $132.00, for a total transaction of $76,296.00. Following the sale, the insider now directly owns 30,201 shares of the company’s stock, valued at $3,986,532. The disclosure for this sale can be found here. Insiders have sold a total of 428,567 shares of company stock valued at $53,420,869 over the last three months. Corporate insiders own 4.08% of the company’s stock.
ALXN stock traded up $0.74 during midday trading on Wednesday, hitting $115.19. The stock had a trading volume of 34,286 shares, compared to its average volume of 1,629,839. The company has a market cap of $25.70 billion, a price-to-earnings ratio of 16.26, a PEG ratio of 1.12 and a beta of 1.64. The company has a current ratio of 4.04, a quick ratio of 3.56 and a debt-to-equity ratio of 0.26. Alexion Pharmaceuticals, Inc. has a 12-month low of $92.56 and a 12-month high of $141.86. The business has a 50-day moving average price of $123.80.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.51. The firm had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. Alexion Pharmaceuticals’s revenue for the quarter was up 15.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.07 EPS. On average, equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9 EPS for the current fiscal year.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Further Reading: What does a market perform rating mean?
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.